Conscious Sedation for Transcatheter Aortic Valve Implantation

Launched by UNIVERSITY OF IOANNINA · Jul 13, 2022

Keywords

ClinConnect Summary

This clinical trial is studying two different methods of conscious sedation during a procedure called Transcatheter Aortic Valve Replacement (TAVR), which is used to treat a heart valve condition called aortic valve stenosis. The researchers want to find out whether using a medication called propofol or another called dexmedetomidine for sedation results in better recovery outcomes for patients. Conscious sedation means that patients are awake and able to respond, but won’t feel pain during the procedure. The goal is to see which option leads to fewer complications and a shorter hospital stay.

To be eligible for the trial, participants need to be scheduled for a TAVR procedure and be between the ages of 65 and 74. However, those with certain conditions, such as severe kidney disease or significant cognitive issues, will not be included. If you participate, you can expect to receive either propofol or dexmedetomidine for sedation during your TAVR, and the medical team will monitor your recovery closely. This trial is important because it aims to improve care for patients undergoing TAVR, especially those who are at higher risk.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients scheduled for TAVR
• Exclusion Criteria:
• • Emergency operation
• • Pre-existing neurocognitive dysfunction (Mini Mental State Examination score \<23)
• • Inability to cooparate - communicate
• • End Stage Renal Disease
• • Allergy to any of the administrated drugs
• • No consent